Skip to main content
SpringerLink
Log in

Potential Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Central retinal vein occlusion (CRVO) remains an important cause of visual loss. Impaired venous drainage leads to retinal hypoxia with upregulation and release of vascular endothelial growth factor (VEGF). VEGF increases vascular permeability and leads to the breakdown of the blood-retinal barrier, with the development of macular oedema. Treatment strategies for macular oedema in CRVO currently under evaluation focus on VEGF blockage. Bevacizumab is a humanized monoclonal antibody that blocks VEGF. It has been evaluated in a clinical trial that compared intravitreal injections of bevacizumab 1.25 mg with sham injections every 6 weeks. At the end of a 24-week follow-up period, 60.0% of patients in the bevacizumab group had gained ≥15 letters compared with 20.0% in the control group (p = 0.003). Aflibercept (previously VEGF Trap-Eye) is a 115kD decoy receptor fusion protein. Aflibercept is capable of binding both VEGF and placental growth factor (PlGF). By blocking both VEGF and PlGF, aflibercept could be more effective than other anti-VEGF drugs. Two clinical trials have evaluated the efficacy of aflibercept for the treatment of macular oedema in CRVO: COPERNICUS and GALILEO. Both included a similar 6-month phase, during which patients were randomized to receive either an intravitreal injection of aflibercept 2 mg or a sham injection every month. In a second 6-month phase of the GALILEO study, patients in the treatment group were treated on an as needed (PRN) basis with aflibercept, while patients in the placebo group continued with sham injections. In the second 6-month phase in the COPERNICUS study, all patients were treated with aflibercept on a PRN basis. Treatment with aflibercept led to an improvement in visual acuity of ≥15 letters in 55.3% (COPERNICUS) and 60.2% of patients (GALILEO). Patients initially in the placebo group and then treated PRN gained only a mean of 3.8 letters, with 30.1% achieving a visual gain of ≥15 letters (COPERNICUS). The percentage of patients that improved by ≥15 letters was 32.4% for the group receiving sham injections throughout the GALILEO study.

In summary, VEGF blockage has been proven to improve visual outcomes in patients with macular oedema due to CRVO. However, an important disadvantage of anti-VEGF drugs is the need for frequent reinjections and even more frequent control visits. Further advances are needed in order to improve quality of life and reduce the burden to healthcare systems.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Fig. 3
Fig. 4
Table II

Similar content being viewed by others

References

  1. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117: 313–9

    Article  PubMed  PubMed Central  Google Scholar 

  2. McIntosh RL, Rogers SL, Lim L, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010; 117: 1113–23

    Article  PubMed  Google Scholar 

  3. No authors listed. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995; 102: 1425–33

    Article  Google Scholar 

  4. No authors listed. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 1995; 102: 1434–44

    Article  Google Scholar 

  5. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480–7

    Article  CAS  PubMed  Google Scholar 

  6. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002; 120: 1644–50

    Article  CAS  PubMed  Google Scholar 

  7. Noma H, Funatsu H, Mimura T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 2009; 116: 87–93

    Article  PubMed  Google Scholar 

  8. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57–65

    Article  PubMed  Google Scholar 

  9. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419–31

    Article  CAS  PubMed  Google Scholar 

  10. Algvere PV, Epstein D, von WG, et al. Intravitreal bevacizumab in central retinal vein occlusion: 18-month results of a prospective clinical trial. Eur J Ophthalmol 2011; 21: 789–95

    Article  PubMed  Google Scholar 

  11. Figueroa MS, Contreras I, Noval S, et al. Results of bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol 2010; 94: 1052–6

    Article  CAS  PubMed  Google Scholar 

  12. Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 2007; 27: 1004–12

    Article  PubMed  Google Scholar 

  13. Rensch F, Jonas JB, Spandau UH. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion. Acta Ophthalmol 2009; 87: 77–81

    Article  PubMed  Google Scholar 

  14. Epstein DL, Algvere PV, von WG, et al. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 2012; 119: 1184–9

    Article  PubMed  Google Scholar 

  15. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1124–33

    Article  PubMed  Google Scholar 

  16. Haller JA, Bandello F, Belfort Jr R, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453–60

    Article  PubMed  Google Scholar 

  17. Yeh WS, Haller JA, Lanzetta P, et al. Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology 2012; 119: 1190–8

    Article  PubMed  Google Scholar 

  18. Scott IU, VanVeldhuisen PC, Oden NL, et al. Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10. Ophthalmology 2011; 118: 345–52

    Article  PubMed  PubMed Central  Google Scholar 

  19. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855–9

    Article  PubMed  Google Scholar 

  20. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003; 9: 47–52

    Article  CAS  PubMed  Google Scholar 

  21. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002 Aug 20; 99(17): 11393–8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008; 92: 667–8

    Article  CAS  PubMed  Google Scholar 

  23. Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011; 118: 1098–106

    Article  PubMed  Google Scholar 

  24. Chong V. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Ophthalmologica 2012; 227 Suppl. 1: 2–10

    Article  CAS  PubMed  Google Scholar 

  25. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology 2012; 119: 1024–32

    Article  PubMed  Google Scholar 

  26. Brown DM, Haller JA, Boyer DS, et al. Intravitreal aflibercept injection in central retinal vein occlusion: 1-year results of the phase 3 COPERNICUS study [poster 936/D980; online]. Available from URL: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=bbef02a2-33ce-49b8-9f80-df7344f29dd9&cKey=78d01ea9-f56f-447e-905b-b8bcf022799e&mKey={F0FCE029-9BF8-4E7C-B48E-9FF7 711D4A0E} [Accessed 2012 Sep 24]

  27. Holz FG, Ogura Y, Roider J, et al. Intravitrial aflibercept injection for macular edema in central retinal vein occlusion: 1-year results of the phase 3 GALILEO study [poster 6929; online]. Available from URL: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=814fffc0-cf7f-4105-8512-7c3124959453&cKey=79b91efa-d330-461e-a9fa-4f5d6905dc36&mKey={F0FCE029-9BF8-4E7C-B48E-9FF 7711D4A0E} [Accessed 2012 Sep 24]

  28. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012 Jul; 119(7): 1388–98

    Article  Google Scholar 

  29. Genentech. Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions (RELATE) [Clinical-Trials.gov identifier NCT01003106]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Sep 15]

Download references

Acknowledgements

No funding was received for the preparation of this manuscript. The authors have no conflict of interests.

Author information

Authors and Affiliations

  1. Instituto Ramón y Cajal de Investigaciones Sanitarias (IRYCIS), Hospital Universitario Ramón y Cajal, Madrid, Spain

    Marta S. Figueroa &  Inés Contreras

  2. Vissum Madrid, Madrid, Spain

    Marta S. Figueroa

  3. Clínica Rementería, Madrid, Spain

    Inés Contreras

Authors
  1. Marta S. Figueroa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Inés Contreras
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Inés Contreras.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Figueroa, M.S., Contreras, I. Potential Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion. Drugs 72, 2063–2071 (2012). https://doi.org/10.2165/11640820-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11640820-000000000-00000

Keywords

Search

Navigation